Methamphetamine Abuse Clinical Trial
Official title:
The Efficacy of Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder
The efficacy of cognitive behavioral therapy(CBT) in treatment of methamphetamine use disorder
Methamphetamine (MA) use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Over the past few years; there is an alarming increase in crystal methamphetamine (Shabu) abuse in the Egyptian market and The Egyptian government is annoyed from this issue because youth within the age of productivity were targeted. Regular methamphetamine use can be associated with a range of psychiatric symptoms, particularly psychosis, anxiety, and depression. No FDA approved pharmacological treatments are available for Meth addiction up till now and despite great advances achieved in understanding the neurobiology of drug addiction, the therapeutic options are severely limited . Consequently, the only available treatment at present is psychosocial intervention. The effectiveness of CBT for other substance-use disorders (e.g. alcohol-, opioid- and cocaine-use disorders) has been well documented and as such this basic treatment approach has been applied to amphetamine-type stimulant (ATS)-use disorder . Currently, there is not enough evidence to establish the efficacy of CBT for amphetamine -type stimulant( ATS) -use disorders because of a paucity of high-quality research in this area. The present study will examine the efficacy of Cognitive behavioral therapy in reducing methamphetamine use in comparison to medical treatment usually taken in methamphetamine use disorder ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
| Completed |
NCT03226223 -
Pharmacogenetics of Naltrexone for Stimulant Abuse
|
Phase 2 | |
| Completed |
NCT02907853 -
Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa
|
N/A | |
| Recruiting |
NCT04616625 -
Cardiovascular Effects of Prenatal Methamphetamine Exposure
|
||
| Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
| Recruiting |
NCT05700994 -
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
|
N/A | |
| Completed |
NCT04109014 -
FASTLANE II: Reducing Sex, Drug, and Mental Health Risk
|
N/A | |
| Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT01822132 -
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
|
N/A | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
| Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
| Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 |